Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > FDA Decision on ImmunityBio's Anktiva tomorrow?

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Apr 22, 2024 7:41pm

167 Views

Post# 36002374

RE:RE:FDA Decision on ImmunityBio's Anktiva tomorrow?

If a combo therapy with similar efficacy and many more treatments which also relies on BCG gets approved, what do you think will happen to us?

DJDawg wrote:
So it has been approved.

Great summary above Eog.

I look forward to the longer term data on Ruvidar to show how much more sustained CR you get with it compared to constant instillations.

It is not exactly a win to tell a patient with bcg failure that they are now signing up for another 18 instilations.